LeMaitre Vascular (NASDAQ:LMAT) Rating Reiterated by Roth Capital

Roth Capital reiterated their neutral rating on shares of LeMaitre Vascular (NASDAQ:LMAT) in a report published on Tuesday morning, Zacks.com reports.

A number of other analysts also recently commented on the company. KeyCorp started coverage on LeMaitre Vascular in a research report on Friday, February 12th. They set a sector weight rating on the stock. Barrington Research boosted their target price on LeMaitre Vascular from $47.00 to $49.00 and gave the stock an outperform rating in a research report on Friday, February 26th. Finally, Zacks Investment Research upgraded LeMaitre Vascular from a hold rating to a buy rating and set a $58.00 target price on the stock in a research report on Tuesday. Four investment analysts have rated the stock with a hold rating and four have given a buy rating to the company’s stock. The company currently has a consensus rating of Buy and a consensus target price of $39.29.

LeMaitre Vascular stock opened at $46.79 on Tuesday. The company has a debt-to-equity ratio of 0.23, a current ratio of 2.30 and a quick ratio of 1.27. LeMaitre Vascular has a 1-year low of $18.76 and a 1-year high of $54.96. The company has a market cap of $951.80 million, a PE ratio of 50.31, a price-to-earnings-growth ratio of 3.52 and a beta of 1.43. The stock’s 50 day moving average price is $47.65 and its 200 day moving average price is $38.19.

LeMaitre Vascular (NASDAQ:LMAT) last posted its quarterly earnings results on Thursday, February 25th. The medical instruments supplier reported $0.34 earnings per share for the quarter, beating the Zacks’ consensus estimate of $0.31 by $0.03. LeMaitre Vascular had a return on equity of 12.32% and a net margin of 15.41%. On average, equities research analysts anticipate that LeMaitre Vascular will post 1 EPS for the current fiscal year.

The business also recently disclosed a quarterly dividend, which will be paid on Thursday, March 25th. Stockholders of record on Tuesday, March 9th will be given a $0.11 dividend. This is an increase from LeMaitre Vascular’s previous quarterly dividend of $0.10. This represents a $0.44 annualized dividend and a dividend yield of 0.94%. The ex-dividend date of this dividend is Monday, March 8th. LeMaitre Vascular’s dividend payout ratio is currently 43.18%.

In related news, Director Lawrence J. Jasinski sold 7,500 shares of the company’s stock in a transaction on Monday, March 1st. The stock was sold at an average price of $51.28, for a total value of $384,600.00. Following the completion of the transaction, the director now directly owns 10,833 shares in the company, valued at $555,516.24. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO George W. Lemaitre sold 42,869 shares of the company’s stock in a transaction on Monday, March 1st. The shares were sold at an average price of $51.41, for a total value of $2,203,895.29. Following the completion of the transaction, the chief executive officer now owns 2,796,567 shares of the company’s stock, valued at $143,771,509.47. The disclosure for this sale can be found here. Insiders sold 128,523 shares of company stock worth $6,295,180 over the last 90 days. Company insiders own 16.50% of the company’s stock.

Institutional investors have recently added to or reduced their stakes in the stock. Fieldpoint Private Securities LLC acquired a new position in LeMaitre Vascular in the fourth quarter valued at $36,000. Steward Partners Investment Advisory LLC increased its stake in LeMaitre Vascular by 41.4% during the fourth quarter. Steward Partners Investment Advisory LLC now owns 1,059 shares of the medical instruments supplier’s stock worth $43,000 after acquiring an additional 310 shares during the last quarter. Lazard Asset Management LLC acquired a new stake in LeMaitre Vascular during the fourth quarter worth about $47,000. BNP Paribas Arbitrage SA increased its stake in LeMaitre Vascular by 327.9% during the third quarter. BNP Paribas Arbitrage SA now owns 4,219 shares of the medical instruments supplier’s stock worth $137,000 after acquiring an additional 3,233 shares during the last quarter. Finally, Citigroup Inc. increased its stake in LeMaitre Vascular by 36.8% during the fourth quarter. Citigroup Inc. now owns 4,296 shares of the medical instruments supplier’s stock worth $174,000 after acquiring an additional 1,155 shares during the last quarter. Hedge funds and other institutional investors own 84.17% of the company’s stock.

LeMaitre Vascular Company Profile

LeMaitre Vascular, Inc designs, markets, sells, services, and supports medical devices and implants for the treatment of peripheral vascular disease worldwide. The company offers angioscope, a fiber optic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries or veins; occlusion catheters that temporarily occlude the blood flow; perfusion catheters to temporarily perfuse the blood and other fluids into the vasculature; and thrombectomy catheters, which features a silicone balloon for removing thrombi in the venous system.

See Also: What is a Futures Contract?

Analyst Recommendations for LeMaitre Vascular (NASDAQ:LMAT)

Receive News & Ratings for LeMaitre Vascular Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for LeMaitre Vascular and related companies with MarketBeat.com's FREE daily email newsletter.